(Bloomberg) -- Pharmaceutical makers won approval from the California Assembly to restrict generic versions of drugs isolated from natural sources, such as vaccines, known as biosimilars, once they become available in the U.S.

The bill passed Monday would require pharmacies to notify doctors and sometimes patients when a cheaper biosimilar drug is substituted for a brand-name medicine. It also would forbid a pharmacist from substituting the biosimilar drug if the physician says no.

Register or login for access to this item and much more

All Employee Benefit News content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access